Trial Site Detail

 

Drug:
QINLOCK Ripretinib DCC-2618
Trial:
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Active, not recruiting

 

MD Anderson Cancer Center

1505 Holcombe Blvd.     
Houston , TX 77030
USA

 

Principal Investigator:
Jon Trent, MD, PhD
Contact:
Clinical Trials Office - M.D. Anderson Cancer Center, 713-792-3245
Activation Status of this Site:
Active
Notes about this Site:
MD Anderson Cancer Center Website:
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.